NovoCure NVCR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's additional paid-in capital?
- NovoCure (NVCR) reported additional paid-in capital of $1.7B in Q1 2026.
- How has NovoCure's additional paid-in capital changed year-over-year?
- NovoCure's additional paid-in capital increased by 9.2% year-over-year, from $1.55B to $1.7B.
- What is the long-term trend for NovoCure's additional paid-in capital?
- Over 5 years (2020 to 2025), NovoCure's additional paid-in capital has grown at a 8.0% compound annual growth rate (CAGR), from $1.11B to $1.63B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.